Revance Therapeutics reported $-67573000 in EBITDA for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Adamas Pharmaceuticals ADMS:US -5502000 3.51M
Aerie Pharmaceuticals AERI:US $ -30.76M 0.92M
ALKERMES ALKS:US $ -0.27M 23.16M
Bristol Myers Squibb BMY:US $ 5712M 33M
Coherus Biosciences CHRS:US $ -31.9M 8.61M
Eli Lilly And LLY:US $ 2437.5M 639.8M
Endo International Ordinary Shares ENDP:US $ 320.03M 5.28M
Flexion Therapeutics FLXN:US $ -23631000 7.27M
Gw Pharmaceuticals GWPH:US $ -17.18M 2.02M
Horizon Pharma HZNP:US $ 439.93M 134.24M
JAZZ PHA JAZZ:US $ 195.95M 118.22M
Johnson & Johnson JNJ:US $ 8192M 2043M
Neurocrine Biosciences NBIX:US $ 47.3M 23.1M
Pacira Pharmaceuticals PCRX:US $ 36.49M 3.4M
Procter & Gamble PG:US $ 5734M 1375M
Revance Therapeutics RVNC:US $ -67.57M 2.28M
Supernus Pharmaceuticals SUPN:US $ 38.61M 2.15M
Teva Pharmaceutical Industries TEVA:US $ 1137M 1M
Zogenix ZGNX:US $ -51.9M 1.17M